Use of macrolides and tetracyclines for chronic inflammatory diseases - PubMed (original) (raw)
Review
doi: 10.1345/aph.1E282. Epub 2004 Nov 23.
Affiliations
- PMID: 15562139
- DOI: 10.1345/aph.1E282
Review
Use of macrolides and tetracyclines for chronic inflammatory diseases
Stacy A Voils et al. Ann Pharmacother. 2005 Jan.
Abstract
Objective: To review the efficacy of macrolides and tetracyclines in several chronic inflammatory conditions.
Data sources: Searches of MEDLINE (1966-March 2004) and an extensive bibliography search were undertaken. Key terms included acne, blepharitis, cardiovascular disease, cystic fibrosis, periodontitis, rosacea, and rheumatoid arthritis.
Study selection and data extraction: Data were obtained primarily from randomized placebo-controlled trials upon which key recommendations are based.
Data synthesis: Antibiotics are often prescribed for months or even years for treatment of chronic inflammatory conditions such as acne, blepharitis, cardiovascular disease, cystic fibrosis, periodontitis, rosacea, and rheumatoid arthritis. Randomized controlled trials have shown that azithromycin is useful in the management of cystic fibrosis and the tetracyclines are beneficial in the management of rheumatoid arthritis, acne, blepharitis, and periodontitis. Several large, randomized controlled trials have failed to show any benefit of macrolides in the secondary prevention of cardiovascular disease. No randomized placebo-controlled clinical trials have been performed to assess the efficacy of macrolides or tetracyclines in patients with rosacea.
Conclusions: The use of tetracyclines and macrolides for rosacea is based primarily on anecdotal reports or open-label trials. Limited clinical trials support the use of tetracyclines or macrolides in acne, blepharitis, periodontitis, rheumatoid arthritis, and cystic fibrosis. Trials to date do not support the use of antibiotics for secondary prevention of cardiovascular disease.
Similar articles
- Tetracyclines: nonantibiotic properties and their clinical implications.
Sapadin AN, Fleischmajer R. Sapadin AN, et al. J Am Acad Dermatol. 2006 Feb;54(2):258-65. doi: 10.1016/j.jaad.2005.10.004. J Am Acad Dermatol. 2006. PMID: 16443056 Review. - Subantimicrobial dose doxycycline for acne and rosacea.
Bikowski JB. Bikowski JB. Skinmed. 2003 Jul-Aug;2(4):234-45. doi: 10.1111/j.1540-9740.2003.03014.x. Skinmed. 2003. PMID: 14673277 Review. - Macrolides in cystic fibrosis.
McArdle JR, Talwalkar JS. McArdle JR, et al. Clin Chest Med. 2007 Jun;28(2):347-60. doi: 10.1016/j.ccm.2007.02.005. Clin Chest Med. 2007. PMID: 17467553 Review. - Macrolides and airway inflammation in children.
Shinkai M, Rubin BK. Shinkai M, et al. Paediatr Respir Rev. 2005 Sep;6(3):227-35. doi: 10.1016/j.prrv.2005.06.005. Paediatr Respir Rev. 2005. PMID: 16153572 Review.
Cited by
- Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.
Benjamin MM, Khalil RA. Benjamin MM, et al. Exp Suppl. 2012;103:209-79. doi: 10.1007/978-3-0348-0364-9_7. Exp Suppl. 2012. PMID: 22642194 Free PMC article. Review. - Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects.
Smith CJ, Sayles H, Mikuls TR, Michaud K. Smith CJ, et al. Arthritis Res Ther. 2011;13(5):R168. doi: 10.1186/ar3491. Epub 2011 Oct 18. Arthritis Res Ther. 2011. PMID: 22008667 Free PMC article. - Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.
Kucukguven A, Khalil RA. Kucukguven A, et al. Curr Drug Targets. 2013 Mar;14(3):287-324. Curr Drug Targets. 2013. PMID: 23316963 Free PMC article. Review. - UPRmt activation improves pathological alterations in cellular models of mitochondrial diseases.
Suárez-Rivero JM, Pastor-Maldonado CJ, Povea-Cabello S, Álvarez-Córdoba M, Villalón-García I, Talaverón-Rey M, Suárez-Carrillo A, Munuera-Cabeza M, Reche-López D, Cilleros-Holgado P, Piñero-Perez R, Sánchez-Alcázar JA. Suárez-Rivero JM, et al. Orphanet J Rare Dis. 2022 May 17;17(1):204. doi: 10.1186/s13023-022-02331-8. Orphanet J Rare Dis. 2022. PMID: 35581596 Free PMC article. - Dry eye disease: an immune-mediated ocular surface disorder.
Stevenson W, Chauhan SK, Dana R. Stevenson W, et al. Arch Ophthalmol. 2012 Jan;130(1):90-100. doi: 10.1001/archophthalmol.2011.364. Arch Ophthalmol. 2012. PMID: 22232476 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical